Valuation
- Market cap
- 69,952,000
- Revenue TTM
- $1,120,000
- Net income TTM
- $-11,170,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -997.32%
- Debt to equity
- 0.00
Trading
- Volume
- 269,300
- Avg volume
- 908,398
- Day's range
- $1.55 – $1.61
- Shares out
- 45,130,000
- Stochastic %K
- 27%
- Beta
- 0.98
- Analysts
- Strong Sell
- Price target
- $7.12
Company profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headqua...
Show more
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 284 4433
- Website
- https://renovorx.com
- Address
- 2570 West El Camino Real, Suite 320, Mountain View, United States
Latest news
No headlines yet.
